



---

## RECEIPT OF APPROVAL IN-PRINCIPLE FROM THE SINGAPORE EXCHANGE SECURITIES TRADING LIMITED (“SGX-ST”) FOR THE TRANSFER LISTING FROM THE CATALIST BOARD OF THE SGX-ST TO THE MAINBOARD OF THE SGX-ST

---

The Board of Directors (the “**Board**” or “**Directors**”) of TalkMed Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the Company’s announcement dated 25 February 2022 (the “**Previous Announcement**”) in relation to its intention to undertake, and its submission of an application to the SGX-ST for a transfer of the listing of the Company from the Catalist Board of the SGX-ST (the “**Catalist**”) to the Mainboard of the SGX-ST (the “**Mainboard**”) (the “**Proposed Transfer**”).

*Unless otherwise defined, capitalised terms used herein shall bear the same meanings ascribed to them in the Previous Announcement.*

The Board is pleased to announce that the Company has on 25 March 2022 obtained the approval in-principle (“**AIP**”) from the SGX-ST in relation to the Proposed Transfer. The AIP is subject to:

- (a) compliance with the SGX-ST’s listing requirements;
- (b) Shareholders’ approval being obtained for the Proposed Transfer via a special resolution under Rule 408(5) of the Listing Manual Section B: Rules of Catalist of the SGX-ST (“**Catalist Rules**”);
- (c) an immediate announcement via SGXNET of the Proposed Transfer; and
- (d) submission of:
  - (i) a written undertaking from the Company in the format set out in Appendix 2.3.1 of the Listing Manual of the SGX-ST (“**Listing Manual**”) to comply with all of the SGX-ST’s requirements and policies applicable to the issuers listed on the Mainboard;
  - (ii) a written undertaking by the Company and its sponsor that they are not aware of any material information which has not been previously announced via SGXNET which will affect the Company’s suitability for the transfer to the Mainboard;
  - (iii) a written undertaking from each of the Company’s directors in the form set out in Appendix 7.7 of the Listing Manual and an undertaking from the Company to procure the same undertaking from any new director appointed to the Company’s Board after the Proposed Transfer takes place; and
  - (iv) a written confirmation from the Company that it is in compliance with all applicable Catalist Rules.

The AIP is not to be taken as an indication of the merits of the Proposed Transfer, the Company, its subsidiaries or its securities.

The Company will be seeking specific approval from its Shareholders for the Proposed Transfer at an extraordinary general meeting (“**EGM**”) to be convened. A circular containing, *inter alia*, the details

of the Proposed Transfer and notice of EGM will be posted on SGXNET and the Company's website at the URL <https://www.talkmed.com.sg/> in due course.

The Company will update Shareholders as and when there are material developments in respect of the Proposed Transfer.

**Shareholders and potential investors should exercise caution when trading in the shares of the Company as there is no certainty or assurance as at the date of this announcement that Shareholders' approval for the Proposed Transfer will be obtained or if the Proposed Transfer will eventually be undertaken at all. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors or other professional advisors if they have any doubt about the actions that they should take or when dealing with their shares of the Company.**

By Order of the Board

Ang Peng Tiam  
Chief Executive Officer  
28 March 2022

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, Hong Leong Finance Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr Kaeson Chui, Vice President, at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581. Telephone number: (65) 6415 9886*